EU
SALE
CLENBUTOS – Driada (EU)
$24.00
Availability: In StockRaw Material: Clenbuterol
Manufacturer: DRIADA
Package: 100 tabs (40mcg/tab)
Quick Comparison
| Settings | CLENBUTOS - Driada (EU) remove | Dianamed 10mg – Methandienone – Deus Medical remove | Letrozone - Letrozole 5mg/100 tabs. remove | Anavamed 10mg – Oxandrolone – Deus Medical remove | Winimed 10mg – Stanozolol – Deus Medical remove | Letrozole 2.5mg – Anti-estrogen, decreases fat build-up and decreases water retention remove |
|---|---|---|---|---|---|---|
| Name | CLENBUTOS - Driada (EU) remove | Dianamed 10mg – Methandienone – Deus Medical remove | Letrozone - Letrozole 5mg/100 tabs. remove | Anavamed 10mg – Oxandrolone – Deus Medical remove | Winimed 10mg – Stanozolol – Deus Medical remove | Letrozole 2.5mg – Anti-estrogen, decreases fat build-up and decreases water retention remove |
| Image |
EU | 
EU | 
EU | 
EU | 
EU | 
EU |
| SKU | driada-eu-006 | 101AAS-DM-0-117 | RF-AlphaZone-upline5233 | 101AAS-DM-0-113 | 101AAS-DM-0-101 | 101AAS-HB-0-139 |
| Rating | ||||||
| Price | $24.00 | $40.00 | $95.99 | $50.00 | $48.00 | $75.00 |
| Stock | Out of stock | Out of stock | ||||
| Availability | Out of stock | Out of stock | ||||
| Add to cart | ||||||
| Description | Raw Material: Clenbuterol Manufacturer: DRIADA Package: 100 tabs (40mcg/tab) |
Active Ingredient: Methandienone 10mg
Count: 100 Tabs
Active Half-life: 5-6 Hours
Classification: Anabolic Steroid
Acne: Yes
Concentration: 10 mg/cap
Presentation: 100 Capsules (Total box 1000mg)
Dosage: 20-80mg per day over the course of 6-8 weeks
| ACTIVE INGREDIENT: LETROZOLE 5mg TABLET COUNT: 100 COUNTS ACTIVE HALF-LIFE: 9 HOURS CLASSIFICATION: ANTI ESTROGEN DOSAGE: 5mg ACNE: NONE WATER RETENTION: NO HBR: NO HEPATOXITY: LOW AROMATIZATION: NO | Active Ingredient: Oxandrolone 10mg Active Half-life: 9 Hours Classification: Anabolic Steroid Dosage Men: 50-100 Mg/day Dosage Women: 5-30 Mg/day Acne: Rarely Water Retention: No Hbr: No Hepatoxity: Low Aromatization: No | Active Ingredient: Stanozolol 10mg Tablet Count: 50 Tablets Active Half-life: 9 Hours Classification: Anabolic Steroid Dosage Men: 20-50 Mg/day Acne: Yes Water Retention: No Hbr: Perhaps Hepatoxity: Yes | CTIVE INGREDIENT: Letrozole 2.5mg TABLET COUNT: 30 COUNTS ACTIVE HALF-LIFE: 9 HOURS CLASSIFICATION: ANABOLIC STEROID DOSAGE: 2.5-5 MG/DAY ACNE: RARELY WATER RETENTION: NO HBR: NO HEPATOXITY: LOW AROMATIZATION: NO Ship From: Europe |
| Content | Letrozole 5mg x 100 tablets Letrozole is a third generation Aromatase Inhibitor (AI) that works by attaching to -and eliminating the aromatase enzyme resposible for producing estrogen. This makes it a perfect choice to combat gynocomastia which it will completely prevent. Letrozole also quite raises LH levels which deems it suitable for post-cycle use. The human body does need estrogen to maintain proper immune function and balance cholesterol ratios in the blood. Since letrozole is so strong at eliminating estrogen, it is not suited for long term use. | Letrozole is a nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production. Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax. Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems. Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature. | ||||
| Weight | N/A | N/A | N/A | N/A | N/A | N/A |
| Dimensions | N/A | N/A | N/A | N/A | N/A | N/A |
| Additional information |
Reviews
There are no reviews yet.